4.47  -0.31 (-6.49%)		01-30 16:00
Open: 4.73 High: 4.91 Volume: 466,198		Pre. Close: 4.78 Low: 4.43 Market Cap: 305(M)

Short term
Mid term
Targets	6-month :	6.19	1-year :	7.23
Resists	First :	5.3	Second :	6.19
Pivot price	4.57
Supports	First :	4.16	Second :	3.46
MAs	MA(5) :	4.86	MA(20) :	4.42
	MA(100) :	2.77	MA(250) :	1.98
MACD	MACD :	0.3	Signal :	0.3
%K %D	K(14,3) :	68.1	D(3) :	79
RSI	RSI(14): 52.4
52-week	High :	5.3	Low :	1.04

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ CLYM ] has closed above bottom band by 43.8%. Bollinger Bands are 44% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	4.91 - 4.95	4.95 - 4.97
Low:	4.37 - 4.4	4.4 - 4.43
Close:	4.43 - 4.47	4.47 - 4.51

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Sat, 24 Jan 2026
Climb Bio, Inc. (NASDAQ:CLYM) Shares Could Be 45% Below Their Intrinsic Value Estimate - Yahoo Finance

Wed, 14 Jan 2026
Analysts Are Bullish on Top Healthcare Stocks: Climb Bio (CLYM), Travere Therapeutics (TVTX) - The Globe and Mail

Fri, 09 Jan 2026
Climb Bio’s CLYM116 Moves Into First-in-Human Testing: What Early Investors Should Watch - TipRanks

Thu, 08 Jan 2026
Climb Bio (NASDAQ: CLYM) details 2026 pipeline plans and cash runway into 2028 - Stock Titan

Thu, 08 Jan 2026
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026 - Yahoo Finance

Thu, 08 Jan 2026
New drug trials target lupus and kidney disease, with 2026 data ahead - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	48 (M)
Shares Float	43 (M)
Held by Insiders	0.8 (%)
Held by Institutions	43.8 (%)
Shares Short	1,820 (K)
Shares Short P.Month	1,880 (K)

EPS	-0.59
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.59
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-17.4 %
Return on Equity (ttm)	-25.7 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-44 (M)
Levered Free Cash Flow	-25 (M)

PE Ratio	-7.58
PEG Ratio	0
Price to Book value	1.71
Price to Sales	0
Price to Cash Flow	-4.83

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.